Sign up now for ease of access to The Medical Independent, Ireland’s most frequently published medical newspaper, delivering award-winning news and investigative reporting.
Established in 2010, along with its sister publication The Medical Independent, our stated aim is to investigate and analyse the major issues affecting healthcare and the medical profession in Ireland. The Medical Independent has won a number of awards for its investigative journalism, and its stories are frequently picked up by national digital, broadcast and print media. The Medical Independent is published by GreenCross Publishing.
Address: Top Floor, 111 Rathmines Road Lr, Dublin 6
Tel: 353 (01) 441 0024
GreenCross Publishing is owned by Graham Cooke.
A resolution on transparency in medicine markets passed at the World Health Assembly (WHA) in Geneva this summer was a “watered-down” version of the original proposal, campaigners have told this newspaper. However, the Access to Medicines Ireland (AMI) group praised the Irish Government for supporting the amended motion.
“AMI were pleased that the resolution to increase transparency on underlying costs of medicines carried,” Dr Kieran Harkin, a member of AMI, told the Medical Independent (MI).
Dr Harkin, a GP in Inchicore, Dublin, added that AMI was “disappointed that this was a watered-down [version] of the original proposal from the Italian government”.
However, he said the group was happy the Irish Government supported the motion.
“We would like to see the Irish Government use its influence to prevent the pharmaceutical industry keeping governments and patients in the dark about research and development costs,” said Dr Harkin.
The WHA is the decision-making body of the World Health Organisation (WHO). The 2019 WHA meeting took place in May in Geneva. The assembly “adopted a resolution on improving the transparency of markets for medicines, vaccines and other health products in an effort to expand access”, according to the WHO’s website. The resolution urges member states, including Ireland, to enhance public sharing of information on actual prices paid by governments and other buyers for health products and for greater transparency on pharmaceutical patents, clinical trial results, and other determinants of pricing along the value chain from laboratory to patient.
A Department of Health spokesperson told MI that “securing timely access to new and innovative medicines is a key objective of the Irish Government.
“However, the challenge is to deliver on that objective in a manner that is affordable and sustainable.”
The Irish Pharmaceutical Healthcare Association has frequently maintained that Ireland lags behind other western European countries on speed of access to innovative medicines.
New GPs should be prepared for the practicalities and business aspects of running a practice, according...
There was almost a three-fold increase in the number of new post applications made to the.
The ICGP is examining alternative pathways for entry into general practice training as part of efforts...
In December, the HSE released part of an external review into the case of 'Brandon', a...
The evidence on doctor burnout “should scare us and concern us”, the Director of the RCSI...
A review of public health governance structures and addressing “longstanding” IT infrastructure...
Leave a Reply
You must be logged in to post a comment.